C. M. Quinn

Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): design of a multicentre, randomised, double-blind, placebo-controlled, parallel-group study

A. Singer, C. Herzog, B. Safdar, 2023, BMJ Open.

Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease.

Á. Valverde, A. Sabirsh, L. Jermutus, 2017, American journal of physiology. Renal physiology.

Molecular Stratification of Chronic Kidney Disease

T. Slidel, W. Ju, V. Nair, 2021, medRxiv.

Inflammation and Inflammatory Mediators in Kidney Disease Inhibition of T-cell activation by the CTLA 4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease

Á. Valverde, A. Sabirsh, L. Jermutus, 2017 .

The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland

T. Ward, Antonio Ramírez de Arellano, Ruth D. Lewis, 2022, PharmacoEconomics - Open.